OPTIMAL THERAPEUTIC REGIMEN FOR RAPID CORRECTION OF ANEMIA DUE TO IRON DEFICIENCY IN PATIENTS WITH ADVANCED HEART FAILURE  by Kaldara, Elisavet et al.
A33.E313
JACC March 9, 2010
Volume 55, issue 10A
 CARDIAC FUNCTION AND HEART FAILURE 
OPTIMAL THERAPEUTIC REGIMEN FOR RAPID CORRECTION OF ANEMIA DUE TO IRON DEFICIENCY IN 
PATIENTS WITH ADVANCED HEART FAILURE
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Monday, March 15, 2010, 3:30 p.m.-4:30 p.m.
Session Title: Anemia and the Cardiorenal Syndrome
Abstract Category: Myocardial Function/Heart Failure--Clinical Pharmacological Treatment
Presentation Number: 1179-61
Authors: Elisavet Kaldara, John Terrovitis, Eleni Tseliou, George Alexopoulos, Vanessa Kontopidi, Zafiria Margari, Argirios Ntalianis, Lampros Katsaros, 
Charis Matsouka, Maria Anastasiou-Nana, John N. Nanas, University of Athens, 3rd Cardiology Dept, Athens, Greece
Background: Anemia, a common complication of heart failure (HF), is an independent adverse prognostic factor. Iron deficiency is a major cause 
of anemia in end-stage HF. We compared the effectiveness of intravenous iron (i.v. Fe) versus darbepoetin alpha (DA) plus i.v. Fe for the treatment of 
anemic patients presenting with HF and iron deficiency.
Methods: Anemia was defined as a hemoglobin (Hgb) concentration <12 g/dl. Anemic patients underwent bone marrow aspiration to evaluate 
their iron stores. Iron deficient patients were randomly assigned to i.v. Fe, 300 mg once/week for 6 weeks, (group 1), versus subcutaneous DA, 50 ug 
+ i.v. Fe, 300 mg, both once/week for 6 weeks (group 2).
Results: Group 1 included 12 and group 2 included 13 patients. The baseline characteristics of the 2 groups were similar (NYHA: 3.5±0.5 vs 
3.6±0.5, p=0.6 , EF:26±9 vs 25±10%, p=0.8, Hb:10.6±1.0 vs 10.3±0.7mg/dl, p=0.4, creatinine:1.4±0.6 vs 1.5±0.7mg/dl, p =0.7, ferritin: 112±70 
vs 113±109ng/ml p=0.9,in group 1 vs. group 2). Both treatments increased Hb significantly and similarly in both groups. A significant increase of b 
was observed within 2 weeks 2 in both groups (table).
Conclusion: Intravenous iron was an effective and safe treatment of iron-deficiency anemia in patients with HF. Adding an erythropoietin-
stimulating agent conferred no additional treatment benefit compared with i.v. Fe alone
Time course of haemoglobin increase in the 2 groups
Baseline Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Group 1 10.6±1.0 11.1±0.8 11.4±1.2 12.0±1.0 11.9±0.8 12.5±1.1 12.5±0.9
Group 2 10.4±0.8 11.1±0.8 11.6±1.1 11.9±1.1 12.0±1.3 12.2±1.3 12.6±1.6
